| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -62,424,863 |
| Amortization | 117,052 |
| Stock-based compensation | 8,897,887 |
| Loss from change in fair value of promissory notes | 6,074,586 |
| Warrant inducement expenses (note 10) | 33,521,874 |
| Gain from change in fair value of warrant liability | -43,015,831 |
| Loss on equity method investment | -141,007 |
| Accounts receivable | 1,490,931 |
| Inventory | 3,338,404 |
| Prepaid expenses and other current assets | -8,011,949 |
| Other assets | 95,247 |
| Operating lease liabilities | -50,131 |
| Accounts payable | 1,666,049 |
| Accrued expenses | 1,710,195 |
| Income taxes payable | -1,554,629 |
| Net cash used in operating activities | -51,829,437 |
| Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs | 25,396,398 |
| Proceeds from exercise of common stock warrants | 22,631,172 |
| Proceeds from debt | 33,100,000 |
| Repayment of debt | 36,142,586 |
| Net cash provided by financing activities | 44,984,984 |
| Net (decrease) increase in cash and cash equivalents | -6,844,453 |
| Cash and cash equivalents at beginning of period | 14,927,538 |
| Cash and cash equivalents at end of period | 8,083,085 |
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)